List view / Grid view
19 March 2025 | By Eurofins DiscoverX
Join Dr Daniela Cipolletta from Seismic Therapeutic to discover how FcγRIIb clustering enabled the discovery of S-4321, a low-affinity PD-1 agonist that restores immune balance by engaging multiple inhibitory pathways.
29 January 2025 | By Eurofins Discovery
Explore how a Weight of Evidence (WoE) approach uses in vitro methods and artificial intelligence (AI) to transform carcinogenicity risk assessment, reducing reliance on animal studies while enhancing compliance with FDA and ICH guidelines.
9 January 2025 | By Eurofins DiscoverX
Gain valuable insights into the latest advancements in obesity drug discovery and enhance your research capabilities.
The LiCellGrow cell expansion system enables real-time metabolic monitoring and automated culture optimisation to accelerate cell and gene therapy manufacturing.
The emergence of new antibody-based therapeutics, such as antibody-drug conjugates, alongside a continued drive towards alternatives to animal testing approaches, highlights the need for precise and sensitive tools enabling the identification and characterisation of the best drug candidates for clinical progression. Capable of keeping up with the evolving drug development…
Sygnature Discovery has created a platform named SCANME, which can scale up human disease modelling to develop novel therapeutics.
Researchers suggest that integrating genetically diverse mouse models with cell-based assays will better replicate human diseases.
2 August 2024 | By Eurofins Discovery
In this webinar, we will present how challenging recombinant protein such as GPCRs are produced and characterised and how biophysics participates in GPCRs hit finding and hit confirmation.
31 July 2024 | By bit.bio
Watch this webinar to discover the latest astrocyte research and its implications for CNS drug discovery.
25 July 2024 | By Eurofins Discovery
Eurofins Discovery’s Luke Oostdyk, PhD, will highlight anti-obesity target combination therapies and cell-based assays ideal for testing functional activity, specificity, potency and signalling mechanisms of desired therapies against multiple disease-relevant targets.
The new agent, DIF-1(+3), proved to be as effective against drug-resistant malaria as it was against susceptible strains.
Blocking the TGF-β signalling pathway produced effective antitumour activity against hepatocellular carcinoma.
17 July 2024 | By Eurofins Discovery
Join this webinar to hear from Eurofins Discovery on the latest offerings for drug-drug interaction assessments using CRISPR KO/KI MDCKII cell lines
Human brain organoids are complex in vitro tools derived from stem cells, designed to model the molecular basis of neurodevelopment and the pathogenesis of neurological disorders. By mimicking the function of the human brain, in both health and disease, their application in drug discovery holds significant potential for identifying new…
The inhibitor, HVH-2930, effectively induced apoptosis in breast cancer cells without initiating the heat shock response.
